| Literature DB >> 34430570 |
Lei Tang1,2, Wuchao Li2, Xianchun Zeng2, Rongpin Wang2, Xiushu Yang3, Guangheng Luo3, Qijian Chen4, Lihui Wang4, Bin Song1.
Abstract
BACKGROUND: Urolithiasis is a global disease with a high incidence and recurrence rate, and stone composition is closely related to the choice of treatment and preventive measures. Calcium oxalate monohydrate (COM) is the most common in clinical practice, which is hard and difficult to fragment. Preoperative identification of its components and selection of effective surgical methods can reduce the risk of patients having a second operation. Methods that can be used for stone composition analysis include infrared spectroscopy, X-ray diffraction, and polarized light microscopy, but they are all performed on stone specimens in vitro after surgery. This study aimed to design and develop an artificial intelligence (AI) model based on unenhanced computed tomography (CT) images of the urinary tract, and to investigate the predictive ability of the model for COM stones in vivo preoperatively, so as to provide surgeons with more accurate diagnostic information.Entities:
Keywords: Calcium oxalate monohydrate (COM); artificial intelligence (AI); component analysis; unenhanced CT
Year: 2021 PMID: 34430570 PMCID: PMC8350703 DOI: 10.21037/atm-21-965
Source DB: PubMed Journal: Ann Transl Med ISSN: 2305-5839
Figure 1Case screening flow chart. COM, calcium oxalate monohydrate; COD, calcium oxalate dihydrate; AUA, anhydrous uric acid; AAU, ammonium urate; MAP, magnesium ammonium phosphate; CA, carbonate apatite.
Figure 2Manual segmentation interface for urinary stones (ITK-SNAP software).
Figure 3Artificial intelligence analysis step-by-step diagram.
Clinical and imaging features of urinary calculi
| Features | COM | Non-COM | P value |
|---|---|---|---|
| Number of samples | 373 | 170 | |
| Gender | |||
| Male | 275 (73.73%) | 108 (63.53%) | 0.016 |
| Female | 98 (26.27%) | 62 (36.47%) | |
| Age | |||
| Total | 45.55±16.14 | 42.25±20.95 | 0.000 |
| Less than 18 years | 23 (6.17%) | 31 (18.24%) | |
| More than 18 years | 350 (93.83%) | 139 (81.76%) | |
| Stone location | |||
| Kidney | 177 (47.45%) | 105 (61.76%) | 0.000 |
| Ureter | 92 (24.66%) | 17 (10.00%) | |
| Bladder | 12 (3.22%) | 20 (11.76%) | |
| Kidney + ureter | 88 (23.59%) | 26 (15.29%) | |
| Kidney + ureter + bladder | 0 (0.00%) | 1 (0.59%) | |
| Kidney + bladder | 4 (1.07%) | 1 (0.59%) | |
| Single/multiple | |||
| Single | 160 (42.90%) | 70 (41.18%) | 0.707 |
| Multiple | 213 (57.10%) | 100 (58.82%) | |
| Stone site | |||
| Left | 161 (44.60%) | 55 (36.67%) | 0.000 |
| Right | 127 (35.18%) | 58 (38.67%) | |
| Bilateral | 73 (20.22%) | 37 (24.67%) | |
| Stone shape | |||
| Staghorn stones | 24 (6.43%) | 40 (23.53%) | 0.000 |
| Non-Staghorn stones | 349 (93.57%) | 130 (76.47%) | |
| Recurrence | |||
| Recurrence rate | 10 (1.8%) | 5 (0.92%) |
COM, calcium oxalate monohydrate.
Figure 4Screening of stone features.
Figure 5Performance of the calcium oxalate monohydrate (COM) model.